TCBIO — Stock Film
STOCK FILMSCENE 1/11TCBIO · $20.57
Stock Expert AI presents
TCBIO
Texas Capital Bancshares, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Texas Capital Bancshares, Inc. A quick introduction.

On the stock market since 2021, it operates in the world of money and finance. It has 1,785 employees. Now — the numbers.

on the stock market since 2021
1,785 employees
$4.5B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $17 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 17%

This is an established company with proven profits.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 19% a year over the last 4 years. Every year shown ended in profit.

$987.1M
2021
$1.2B
2022
$1.8B
2023
$1.8B
2024
$2B
2025
Every quarter, analysts set a profit bar.
How many of the last 5 did the company clear?
5 / 5
EXPECTATIONS MET OR BEATEN
5
Apr 2025
Jul 2025
Oct 2025
Jan 2026
Apr 2026
5 TIMES IN THE LAST 5 QUARTERS
It clears the bar, quarter after quarter.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
86
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
39
weak

For a bank, strength is measured by capital buffers and reserves — not cash minus debt.

VALUATION
81
very strong

The price looks reasonable next to what the company earns.

GROWTH
98
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
24
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Financial Strength: The capital buffer looks thin next to its class; less room to absorb a rough stretch.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
Heavy bets against the stock2/10
The stock has lost its spark3/10
WORTH WATCHING

Bets Against the Stock: The number of investors betting on a fall stands out.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 27% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
A fat but narrowing margin

The net profit margin is 17% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/3
Sales keep climbing

Over the last 3 years, sales grew about 17% a year on average.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 74 buys and 62 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 24/100. For a turnaround signal, the stock first needs to close the gap with the market.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 39/100.

3
THE RISKS · 3/3
Heavy bets against the stock

The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.

FINALE · THE GRADE
B
0 / 100 · MoonshotScore

On our five-subject report card, TCBIO sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: TCBIO is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film